CN100372535C - 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途 - Google Patents

4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途 Download PDF

Info

Publication number
CN100372535C
CN100372535C CNB038227118A CN03822711A CN100372535C CN 100372535 C CN100372535 C CN 100372535C CN B038227118 A CNB038227118 A CN B038227118A CN 03822711 A CN03822711 A CN 03822711A CN 100372535 C CN100372535 C CN 100372535C
Authority
CN
China
Prior art keywords
vitamin
csf
combination
pyridylmethyl
mds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038227118A
Other languages
English (en)
Chinese (zh)
Other versions
CN1684684A (zh
Inventor
M·H·杜根
A·利斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona State University Represented By Arizona Board Of Directors
Novartis AG
Original Assignee
Arizona State University Represented By Arizona Board Of Directors
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona State University Represented By Arizona Board Of Directors, Novartis AG filed Critical Arizona State University Represented By Arizona Board Of Directors
Publication of CN1684684A publication Critical patent/CN1684684A/zh
Application granted granted Critical
Publication of CN100372535C publication Critical patent/CN100372535C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038227118A 2002-09-24 2003-09-23 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途 Expired - Fee Related CN100372535C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
US60/413,176 2002-09-24

Publications (2)

Publication Number Publication Date
CN1684684A CN1684684A (zh) 2005-10-19
CN100372535C true CN100372535C (zh) 2008-03-05

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038227118A Expired - Fee Related CN100372535C (zh) 2002-09-24 2003-09-23 4-吡啶基甲基-酞嗪衍生物在制备治疗骨髓增生异常综合征的药物中的用途

Country Status (22)

Country Link
US (1) US20060128716A1 (enExample)
EP (1) EP1545534B1 (enExample)
JP (1) JP2006502195A (enExample)
KR (1) KR20050074450A (enExample)
CN (1) CN100372535C (enExample)
AT (1) ATE359789T1 (enExample)
AU (1) AU2003299065B2 (enExample)
BR (1) BR0314647A (enExample)
CA (1) CA2499738A1 (enExample)
CR (1) CR7754A (enExample)
DE (1) DE60313344T2 (enExample)
EC (1) ECSP055700A (enExample)
ES (1) ES2285251T3 (enExample)
HR (1) HRP20050281A2 (enExample)
MX (1) MXPA05003161A (enExample)
NO (1) NO20051936L (enExample)
PL (1) PL374696A1 (enExample)
PT (1) PT1545534E (enExample)
RS (1) RS20050228A (enExample)
RU (1) RU2353364C2 (enExample)
WO (1) WO2004028542A1 (enExample)
ZA (1) ZA200502212B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251097A (zh) * 1997-02-13 2000-04-19 诺瓦提斯公司 具有血管生成抑制活性的酞嗪类化合物
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
WO2001010859A1 (en) * 1999-08-10 2001-02-15 Bayer Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
EP1246617B1 (en) * 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251097A (zh) * 1997-02-13 2000-04-19 诺瓦提斯公司 具有血管生成抑制活性的酞嗪类化合物
WO2000059509A1 (en) * 1999-03-30 2000-10-12 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
WO2001010859A1 (en) * 1999-08-10 2001-02-15 Bayer Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity

Also Published As

Publication number Publication date
ZA200502212B (en) 2006-02-22
DE60313344D1 (de) 2007-05-31
WO2004028542A1 (en) 2004-04-08
EP1545534A1 (en) 2005-06-29
US20060128716A1 (en) 2006-06-15
CA2499738A1 (en) 2004-04-08
AU2003299065B2 (en) 2006-10-26
RU2005112711A (ru) 2006-02-27
JP2006502195A (ja) 2006-01-19
ES2285251T3 (es) 2007-11-16
ECSP055700A (es) 2005-08-11
MXPA05003161A (es) 2005-09-12
PT1545534E (pt) 2007-06-22
KR20050074450A (ko) 2005-07-18
HRP20050281A2 (en) 2006-07-31
CN1684684A (zh) 2005-10-19
BR0314647A (pt) 2005-08-02
ATE359789T1 (de) 2007-05-15
RS20050228A (sr) 2007-08-03
NO20051936L (no) 2005-06-23
DE60313344T2 (de) 2008-01-03
RU2353364C2 (ru) 2009-04-27
AU2003299065A1 (en) 2004-04-19
EP1545534B1 (en) 2007-04-18
CR7754A (es) 2005-12-02
PL374696A1 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
WO2020211860A1 (zh) 用于治疗尤因肉瘤的喹啉类化合物或其药学上可接受的盐
CN1511036B (zh) 包含信号转导抑制剂和埃坡霉素衍生物的联合形式
US20030096852A1 (en) Human growth hormone antagonists
JP2012516354A (ja) 乳癌を治療するための方法及び組成物
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
NZ550174A (en) Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof
KR20220124739A (ko) 암의 치료를 위한 병용 요법
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1545534B1 (en) Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes
WO2007022042A2 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
CN111840289A (zh) 用于治疗骨巨细胞瘤的喹啉类化合物或其药学上可接受的盐
JP2020537689A (ja) Ａ−ノル−５αアンドロスタン化合物を含む白血球増多製剤およびその使用
US20080312250A1 (en) Combination Comprising a Bcrp Inhibitor and 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3- (4-Pyridin-3-Yl) Pyrimidin-2-Ylamino) Phenyl] -Benzamide
US20090233939A1 (en) Treatment of amm
AU2020346384A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
JP2023514426A5 (enExample)
EP4640218A1 (en) Use of sultam compound in treating biliary tract cancer
CN119454969A (zh) 含pd-l1小分子抑制剂的药物组合及其应用
WO2026107242A1 (en) Ras and pd-1 or pd-l1 inhibitors combination therapy
JP2006502195A5 (enExample)
JP2005507410A (ja) Ｂｃｒ／ａｂｌキナーゼ活性のＡＴＰ競合的阻害剤とチロホスチンアナログとの組合せ剤
US20090239872A1 (en) Treatment of mesothelioma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080305

Termination date: 20100923